Presentation is loading. Please wait.

Presentation is loading. Please wait.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.

Published byMavis Allison Modified over 6 years ago

Similar presentations

Presentation on theme: "Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi."— Presentation transcript:

1 Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi Ngoc Lan Vuong, M.D., Manh Tuong Ho, M.D., Tan Duc Ha, M.D., Huy Tuan Phung, M.D., Gia Bao Huynh, M.Sc., Peter Humaidan, D.M.Sc.  Fertility and Sterility  Volume 105, Issue 2, Pages (February 2016) DOI: /j.fertnstert Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

2 Figure 1 CONSORT flow diagram. AMH = antimüllerian hormone; COS = controlled ovarian stimulation; OPU = oocyte pick-up; PCOS = polycystic ovary syndrome. Fertility and Sterility  , DOI: ( /j.fertnstert ) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

3 Figure 2 Serum concentrations (mean ± SD) of LH (A), FSH (B), E2 (C), and P (D) during the follicular phase and early luteal phase by treatment group (GnRH-a [triptorelin] dose). *P<.05 for LH and P. OPU = oocyte pick-up. Fertility and Sterility  , DOI: ( /j.fertnstert ) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Download ppt "Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi."

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice  Lysanne.

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice  Lysanne.
Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome.

Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome.
Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M
Vuong Thi Ngoc Lan, Nguyen Khanh Linh, Ho Manh Tuong, P. C

Vuong Thi Ngoc Lan, Nguyen Khanh Linh, Ho Manh Tuong, P. C
Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.

Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,
Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.

Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.
Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin- releasing hormone receptor antagonist in healthy women with normal ovulation.

Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin- releasing hormone receptor antagonist in healthy women with normal ovulation.
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D
Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase  Michael von Wolff, M.D., Christian J. Thaler,

Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase  Michael von Wolff, M.D., Christian J. Thaler,
Ovarian morphology and function during growth hormone therapy of short girls born small for gestational age  Jeanette Tinggaard, M.D., Rikke Beck Jensen,

Ovarian morphology and function during growth hormone therapy of short girls born small for gestational age  Jeanette Tinggaard, M.D., Rikke Beck Jensen,
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome  Sigrun B. Kjøtrød, M.D., Arne.

Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome  Sigrun B. Kjøtrød, M.D., Arne.
Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist.

Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist.

Similar presentations

Ads by Google